FMC CORP (FMC) Form 8-K — Jul 29, 2026
FMC Corporation reported second quarter 2026 revenue of $867 million, down 17 percent versus the prior year, with a consolidated GAAP net loss of $187 million. Adjusted EBITDA was $153 million, down 26 percent year-over-year, though the company noted this metric exceeded the high end of its guidance range. The company concluded its strategic review and announced agreements to sell its India commercial business for $252 million and license rimisoxafen to Corteva for an upfront payment of $200 million. These transactions, along with a $400 million equity investment from Tessenderlo Group, are expected to generate approximately $1 billion in proceeds dedicated to debt reduction.
Key figures
- Eps
- -1.49
- Revenue
- 867000000
- Revenue Yoy
- -17%
- Cash Position
- 476600000
- Adjusted EPS
- 0.26
- Free Cash Flow
- 357000000
- Adjusted EBITDA
- 153000000
- India Sale Price
- 252000000
- Revenue Ex India
- 841000000
- Organic Revenue Change
- -22%
- Rimisoxafen Licensing Payment
- 200000000
- Tessenderlo Equity Investment
- 400000000
Price after filing
Close on the filing date to close N calendar days later (from $11.12). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.